Evogene (EVGN) Common Equity (2014 - 2025)
Evogene (EVGN) posted Common Equity of -$82000.0 for Q4 2025, down 100.66% sequentially from $12.4 million in Q2 2025, and up 94.35% YoY from -$42192.2 in Q4 2024.
Evogene (EVGN) Common Equity (2014 - 2025) Analysis & Trends
Evogene has reported Common Equity for 12 years, with the latest figure at -$82000.0 in Q4 2025.
- Quarterly Common Equity rose 94.35% year-over-year to -$82000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$82000.0 (up 94.35% YoY) and the FY2025 annual result came in at -$82000.0, up 94.35% from the prior year.
- Common Equity fell to -$82000.0 in Q4 2025 per EVGN's latest filing, from $12.4 million in the prior quarter.
- Over five years, Common Equity peaked at $82.1 million in Q1 2021 and troughed at -$1.5 million in Q4 2024.
- A 5-year average of $34.7 million and a median of $29.8 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2024: Common Equity surged 395.09% in 2021, then slumped 112.04% in 2024.
- Over 5 years, Common Equity stood at $53.7 million in 2021, then plunged by 47.94% to $27.9 million in 2022, then plunged by 56.85% to $12.1 million in 2023, then plunged by 112.04% to -$1.5 million in 2024, then soared by 94.35% to -$82000.0 in 2025.
- According to Business Quant data, Common Equity over the past three periods registered -$82000.0, $12.4 million, and -$1.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -82,000.00 |
| Jun 30, 2025 | 12.38 Mn |
| Dec 31, 2024 | -1.45 Mn |
| Sep 30, 2024 | 12.24 Mn |
| Jun 30, 2024 | 19.94 Mn |
| Mar 31, 2024 | 25.38 Mn |
| Dec 31, 2023 | 12.05 Mn |
| Sep 30, 2023 | 35.86 Mn |
| Jun 30, 2023 | 31.11 Mn |
| Mar 31, 2023 | 28.50 Mn |
| Dec 31, 2022 | 27.93 Mn |
| Sep 30, 2022 | 38.30 Mn |
| Jun 30, 2022 | 45.40 Mn |
| Mar 31, 2022 | 54.73 Mn |
| Dec 31, 2021 | 53.65 Mn |
| Sep 30, 2021 | 70.76 Mn |
| Jun 30, 2021 | 76.64 Mn |
| Mar 31, 2021 | 82.10 Mn |
| Dec 31, 2020 | 10.84 Mn |
| Sep 30, 2020 | 56.07 Mn |